title: New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus.
abstract: Previously we demonstrated the versatile utility of the Parapoxvirus Orf virus (ORFV) as a vector platform for the development of potent recombinant vaccines. In this study we present the generation of new ORFV recombinants expressing the hemagglutinin (HA) or nucleoprotein (NP) of the highly pathogenic avian influenza virus (HPAIV) H5N1. Correct foreign gene expression was examined in vitro by immunofluorescence, Western blotting and flow cytometry. The protective potential of both recombinants was evaluated in the mouse challenge model. Despite adequate expression of NP, the recombinant D1701-V-NPh5 completely failed to protect mice from lethal challenge. However, the H5 HA-expressing recombinant D1701-V-HAh5n mediated solid protection in a dose-dependent manner. Two intramuscular (i.m.) injections of the HA-expressing recombinant protected all animals from lethal HPAIV infection without loss of body weight. Notably, the immunized mice resisted cross-clade H5N1 and heterologous H1N1 (strain PR8) influenza virus challenge. In vivo antibody-mediated depletion of CD4-positive and/or CD8-posititve T-cell subpopulations during immunization and/or challenge infection implicated the relevance of CD4-positive T-cells for induction of protective immunity by D1701-V-HAh5n, whereas the absence of CD8-positive T-cells did not significantly influence protection. In summary, this study validates the potential of the ORFV vectored vaccines also to combat HPAIV.
authors.affiliation: Institute of Immunology, Friedrich-Loeffler-Institute, Federal Research Institute for Animal Health, Island of Riems, Greifswald, Germany.
authors.forename: Jörg
authors.initials: J
authors.lastname: Rohde
authors.affiliation: Institute of Immunology, Friedrich-Loeffler-Institute, Federal Research Institute for Animal Health, Island of Riems, Greifswald, Germany.
authors.forename: Ralf
authors.initials: R
authors.lastname: Amann
authors.affiliation: Institute of Immunology, Friedrich-Loeffler-Institute, Federal Research Institute for Animal Health, Island of Riems, Greifswald, Germany.
authors.forename: Hanns-Joachim
authors.initials: HJ
authors.lastname: Rziha
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D002522:Chlorocebus aethiops; D004274:DNA, Recombinant / Q000235:genetics; D015870:Gene Expression; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics* / Q000276:immunology*; D007114:Immunization; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D051379:Mice; D009698:Nucleoproteins / Q000235:genetics / Q000276:immunology; D009923:Orf virus / Q000235:genetics*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014709:Vero Cells; D014765:Viral Vaccines / Q000235:genetics* / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D004274:DNA, Recombinant; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D009698:Nucleoproteins; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; C109963:hemagglutinin, avian influenza A virus